DNA甲基化与肺动脉高压患病风险相关性的研究进展(3)
[2] Gaine SP，Rubin LJ.Primary pulmonary hypertension.Lancet，1998，352 (9129)：719-725.
[3] Galiè N，Humbert M，Vachiery JL， Gibbs S，Lang I，Torbicki A，Simonneau G，Peacock A，Vonk Noordegraaf A，Beghetti M，Ghofrani A，Gomez Sanchez MA，Hansmann G，Klepetko W，Lancellotti P，Matucci M，McDonagh T，Pierard LA，Trindade PT，Zompatori M，Hoeper M，Aboyans V，Vaz Carneiro A，Achenbach S，Agewall S，Allanore Y，Asteggiano R，Paolo Badano L，Albert Barberà J，Bouvaist H，Bueno H，Byrne RA，Carerj S，Castro G，Erol ，Falk V，Funck-Brentano C，Gorenflo M，Granton J，Iung B，Kiely DG，Kirchhof P，Kjellstrom B，Landmesser U，Lekakis J，Lionis C，Lip GY，Orfanos SE，Park MH，Piepoli MF，Ponikowski P，Revel MP，Rigau D，Rosenkranz S，Vller H，Luis Zamorano J.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension：the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS)： Endorsed by：Association for European Paediatric and Congenital Cardiology(APEC)，International Society for Heart and Lung Transplantation(ISHLT). Eur Heart J，2016，37(1)：67-119.
, http://www.100md.com
[4] Hoeper MM，Bogaard HJ，Condliffe R， Frantz R，Khanna D，Kurzyna M，Langleben D，Manes A，Satoh T，Torres F，Wilkins MR，Badesch DB.Definitions and diagnosis of pulmonary hypertension.Turk Kardiyol Dern Ars，2014，42(suppl 1)：55-66.
[5] Nider V.Pulmonary arterial hypertension.Recognition is the first essential step.Adv NPs Pas，2013，4(5)：33-37.
[6] Aldred MA，Comhair SA，Varella-Garcia M， Asosingh K，Xu W，Noon GP，Thistlethwaite PA，Tuder RM，Erzurum SC，Geraci MW，Coldren CD.Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.Am J Respir Crit Care Med，2010，182(9)：1153-1160.
, 百拇医药
[7] Wang Y， Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor Ⅱ expression in scleroderma.J Cell Mol Med，2013，17(10)：1291-1299.
[8] 周原，陸才德.DNA甲基化作为诊断标记物在胰腺癌诊断中的研究进展.新医学，2016，47(6)：349-353.
[9] Pullamsetti SS，Schermuly R，Ghofrani A，Weissmann N，Grimminger F，Seeger W.Novel and emerging the rapies for pulmonary hypertension.Am J Respir Crit Care Med，2014，189(4)：394-400.
[10] Nakao M.Epigenetics：interaction of DNA methylation and chromatin. Gene，2001，278(1-2)：25-31.
, 百拇医药
[11] 邱烈.CpG岛甲基化异常的致癌作用.检验医学与临床，2007，4(8)：746-748.
[12] Hiltunen MO，Yl-Herttuala S.DNA methylation，smooth musclecells，and atherogenesis.Arterioscler Thromb Vasc Biol，2003，23(10)：1750-1753.
[13] Garrido-Martin EM，Blanco FJ，Fernandez-L A，Langa C，Vary CP，Lee UE，Friedman SL，Botella LM，Bernabeu C. Characterization of the human activin-A receptor type Ⅱ-like kinase 1(ACVRL1)promoter and its regulation by Sp1.BMC Mol Biol，2010，11(1)：1-22., 百拇医药(朱才民 李旎 孙乐波 郑大为 石活顺 徐国栋 邵国丰)
[3] Galiè N，Humbert M，Vachiery JL， Gibbs S，Lang I，Torbicki A，Simonneau G，Peacock A，Vonk Noordegraaf A，Beghetti M，Ghofrani A，Gomez Sanchez MA，Hansmann G，Klepetko W，Lancellotti P，Matucci M，McDonagh T，Pierard LA，Trindade PT，Zompatori M，Hoeper M，Aboyans V，Vaz Carneiro A，Achenbach S，Agewall S，Allanore Y，Asteggiano R，Paolo Badano L，Albert Barberà J，Bouvaist H，Bueno H，Byrne RA，Carerj S，Castro G，Erol ，Falk V，Funck-Brentano C，Gorenflo M，Granton J，Iung B，Kiely DG，Kirchhof P，Kjellstrom B，Landmesser U，Lekakis J，Lionis C，Lip GY，Orfanos SE，Park MH，Piepoli MF，Ponikowski P，Revel MP，Rigau D，Rosenkranz S，Vller H，Luis Zamorano J.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension：the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS)： Endorsed by：Association for European Paediatric and Congenital Cardiology(APEC)，International Society for Heart and Lung Transplantation(ISHLT). Eur Heart J，2016，37(1)：67-119.
, http://www.100md.com
[4] Hoeper MM，Bogaard HJ，Condliffe R， Frantz R，Khanna D，Kurzyna M，Langleben D，Manes A，Satoh T，Torres F，Wilkins MR，Badesch DB.Definitions and diagnosis of pulmonary hypertension.Turk Kardiyol Dern Ars，2014，42(suppl 1)：55-66.
[5] Nider V.Pulmonary arterial hypertension.Recognition is the first essential step.Adv NPs Pas，2013，4(5)：33-37.
[6] Aldred MA，Comhair SA，Varella-Garcia M， Asosingh K，Xu W，Noon GP，Thistlethwaite PA，Tuder RM，Erzurum SC，Geraci MW，Coldren CD.Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.Am J Respir Crit Care Med，2010，182(9)：1153-1160.
, 百拇医药
[7] Wang Y， Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor Ⅱ expression in scleroderma.J Cell Mol Med，2013，17(10)：1291-1299.
[8] 周原，陸才德.DNA甲基化作为诊断标记物在胰腺癌诊断中的研究进展.新医学，2016，47(6)：349-353.
[9] Pullamsetti SS，Schermuly R，Ghofrani A，Weissmann N，Grimminger F，Seeger W.Novel and emerging the rapies for pulmonary hypertension.Am J Respir Crit Care Med，2014，189(4)：394-400.
[10] Nakao M.Epigenetics：interaction of DNA methylation and chromatin. Gene，2001，278(1-2)：25-31.
, 百拇医药
[11] 邱烈.CpG岛甲基化异常的致癌作用.检验医学与临床，2007，4(8)：746-748.
[12] Hiltunen MO，Yl-Herttuala S.DNA methylation，smooth musclecells，and atherogenesis.Arterioscler Thromb Vasc Biol，2003，23(10)：1750-1753.
[13] Garrido-Martin EM，Blanco FJ，Fernandez-L A，Langa C，Vary CP，Lee UE，Friedman SL，Botella LM，Bernabeu C. Characterization of the human activin-A receptor type Ⅱ-like kinase 1(ACVRL1)promoter and its regulation by Sp1.BMC Mol Biol，2010，11(1)：1-22., 百拇医药(朱才民 李旎 孙乐波 郑大为 石活顺 徐国栋 邵国丰)